239 related articles for article (PubMed ID: 16061912)
1. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N; Bonnet MC; Dréno B; Khammari A; Dorval T; Piperno-Neumann S; Liénard D; Speiser D; Marchand M; Brichard VG; Escudier B; Négrier S; Dietrich PY; Maraninchi D; Osanto S; Meyer RG; Ritter G; Moingeon P; Tartaglia J; van der Bruggen P; Coulie PG; Boon T
J Clin Oncol; 2005 Dec; 23(35):9008-21. PubMed ID: 16061912
[TBL] [Abstract][Full Text] [Related]
2. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.
Connerotte T; Van Pel A; Godelaine D; Tartour E; Schuler-Thurner B; Lucas S; Thielemans K; Schuler G; Coulie PG
Cancer Res; 2008 May; 68(10):3931-40. PubMed ID: 18483279
[TBL] [Abstract][Full Text] [Related]
3. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1.
Hanagiri T; van Baren N; Neyns B; Boon T; Coulie PG
Cancer Immunol Immunother; 2006 Feb; 55(2):178-84. PubMed ID: 16187089
[TBL] [Abstract][Full Text] [Related]
4. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.
Spaner DE; Astsaturov I; Vogel T; Petrella T; Elias I; Burdett-Radoux S; Verma S; Iscoe N; Hamilton P; Berinstein NL
Cancer; 2006 Feb; 106(4):890-9. PubMed ID: 16404742
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.
Karanikas V; Lurquin C; Colau D; van Baren N; De Smet C; Lethé B; Connerotte T; Corbière V; Demoitié MA; Liénard D; Dréno B; Velu T; Boon T; Coulie PG
J Immunol; 2003 Nov; 171(9):4898-904. PubMed ID: 14568971
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
[TBL] [Abstract][Full Text] [Related]
7. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.
Lonchay C; van der Bruggen P; Connerotte T; Hanagiri T; Coulie P; Colau D; Lucas S; Van Pel A; Thielemans K; van Baren N; Boon T
Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14631-8. PubMed ID: 15452345
[TBL] [Abstract][Full Text] [Related]
8. Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes.
Trakatelli M; Toungouz M; Lambermont M; Heenen M; Velu T; Bruyns C
Cancer Gene Ther; 2005 Jun; 12(6):552-9. PubMed ID: 15665821
[TBL] [Abstract][Full Text] [Related]
9. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
[TBL] [Abstract][Full Text] [Related]
10. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.
Kazaks A; Balmaks R; Voronkova T; Ose V; Pumpens P
Biotechnol J; 2008 Nov; 3(11):1429-36. PubMed ID: 18956370
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
Reynolds SR; Zeleniuch-Jacquotte A; Shapiro RL; Roses DF; Harris MN; Johnston D; Bystryn JC
Clin Cancer Res; 2003 Feb; 9(2):657-62. PubMed ID: 12576432
[TBL] [Abstract][Full Text] [Related]
12. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
[TBL] [Abstract][Full Text] [Related]
13. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.
Germeau C; Ma W; Schiavetti F; Lurquin C; Henry E; Vigneron N; Brasseur F; Lethé B; De Plaen E; Velu T; Boon T; Coulie PG
J Exp Med; 2005 Jan; 201(2):241-8. PubMed ID: 15657293
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
15. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.
So T; Hanagiri T; Chapiro J; Colau D; Brasseur F; Yasumoto K; Boon T; Coulie PG
Cancer Immunol Immunother; 2007 Feb; 56(2):259-69. PubMed ID: 16758204
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G
Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718
[TBL] [Abstract][Full Text] [Related]
17. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
18. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
20. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.
Godelaine D; Carrasco J; Brasseur F; Neyns B; Thielemans K; Boon T; Van Pel A
Cancer Immunol Immunother; 2007 Jun; 56(6):753-9. PubMed ID: 17096150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
